KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Current Assets (2016 - 2025)

BeOne Medicines (ONC) has disclosed Current Assets for 11 consecutive years, with -$2.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 148.98% to -$2.0 billion in Q4 2025 year-over-year; TTM through Sep 2025 was $5.7 billion, a N/A change, with the full-year FY2025 number at -$2.0 billion, down 148.98% from a year prior.
  • Current Assets was -$2.0 billion for Q4 2025 at BeOne Medicines, down from $5.7 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $7.6 billion in Q4 2021 to a low of -$2.0 billion in Q4 2025.
  • A 5-year average of $3.8 billion and a median of $4.6 billion in 2021 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 395.16% in 2025; the steepest drop was 148.98% in 2025.
  • BeOne Medicines' Current Assets stood at $7.6 billion in 2021, then tumbled by 59.33% to $3.1 billion in 2022, then plummeted by 51.26% to $1.5 billion in 2023, then soared by 164.44% to $4.0 billion in 2024, then crashed by 148.98% to -$2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Current Assets are -$2.0 billion (Q4 2025), $5.7 billion (Q3 2025), and $4.0 billion (Q4 2024).